Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation

Experimental Cell Research

Volumn 315, Issue 15, 2009, Pages 2658-2672

  Chen, Ruey Shyang ^a   Jhan, Jhih Yuan ^a   Su, Ying Jhen ^a   Lee, Wei Ting ^a   Cheng, Chao Min ^a   Ciou, Shih Ci ^a   Lin, Szu Ting ^a   Chuang, Show Mei ^b   Ko, Jen Chung ^c   Lin, Yun Wei ^a  

^a NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c Hsinchu General Hospital   (Taiwan)

Author keywords

Emodin; ERK1 2; Gefitinib; Non small cell lung cancer; Rad51

Indexed keywords

EMODIN; GEFITINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; RAD51 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; ENZYME INACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 67651045814     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.06.002     Document Type: Article

References (53)

1. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19 (1995) 183-232
2. Arteaga C.L. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J. Clin. Oncol. 21 (2003) 289s-291s
3. Raymond E., Faivre S., and Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 Suppl. 1 (2000) 15-23 discussion 41-12
4. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev., Mol. Cell Biol. 2 (2001) 127-137
5. Earp H.S., Dawson T.L., Li X., and Yu H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat. 35 (1995) 115-132
6. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60 Suppl. 1 (2000) 25-32 discussion 41-22
7. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 8 (2001) 3-9
8. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., Rischin D., Eek R., Horai T., Noda K., Takata I., Smit E., Averbuch S., Macleod A., Feyereislova A., Dong R.P., and Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21 (2003) 2237-2246
9. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., Albain K.S., Cella D., Wolf M.K., Averbuch S.D., Ochs J.J., and Kay A.C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
10. Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., Fujii T., and Kuwano M. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 3 (2004) 465-472
11. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
12. Rosell R., Taron M., Reguart N., Isla D., and Moran T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin. Cancer Res. 12 (2006) 7222-7231
13. Demirezer L.O., Kuruuzum-Uz A., Bergere I., Schiewe H.J., and Zeeck A. The structures of antioxidant and cytotoxic agents from natural source: anthraquinones and tannins from roots of Rumex patientia. Phytochemistry 58 (2001) 1213-1217
14. Kuo Y.C., Tsai W.J., Meng H.C., Chen W.P., Yang L.Y., and Lin C.Y. Immune responses in human mesangial cells regulated by emodin from Polygonum hypoleucum Ohwi. Life Sci. 68 (2001) 1271-1286
15. Yagi T., and Yamauchi K. Synergistic effects of anthraquinones on the purgative activity of rhein anthrone in mice. J. Pharm. Pharmacol. 51 (1999) 93-95
16. Matsuda H., Shimoda H., Morikawa T., and Yoshikawa M. Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity. Bioorg. Med. Chem. Lett. 11 (2001) 1839-1842
17. Shi Y.Q., Fukai T., Sakagami H., Kuroda J., Miyaoka R., Tamura M., Yoshida N., and Nomura T. Cytotoxic and DNA damage-inducing activities of low molecular weight phenols from rhubarb. Anticancer Res. 21 (2001) 2847-2853
18. Heo S.K., Yun H.J., Park W.H., and Park S.D. Emodin inhibits TNF-alpha-induced human aortic smooth-muscle cell proliferation via caspase- and mitochondrial-dependent apoptosis. J. Cell. Biochem. 105 (2008) 70-80
19. Su Y.T., Chang H.L., Shyue S.K., and Hsu S.L. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem. Pharmacol. 70 (2005) 229-241
20. Zhang L., Lau Y.K., Xi L., Hong R.L., Kim D.S., Chen C.F., Hortobagyi G.N., Chang C., and Hung M.C. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16 (1998) 2855-2863
21. Zhang L., Lau Y.K., Xia W., Hortobagyi G.N., and Hung M.C. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin. Cancer Res. 5 (1999) 343-353
22. Chen Y.C., Shen S.C., Lee W.R., Hsu F.L., Lin H.Y., Ko C.H., and Tseng S.W. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem. Pharmacol. 64 (2002) 1713-1724
23. Shieh D.E., Chen Y.Y., Yen M.H., Chiang L.C., and Lin C.C. Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sci. 74 (2004) 2279-2290
24. Wang C., Wu X., Chen M., Duan W., Sun L., Yan M., and Zhang L. Emodin induces apoptosis through caspase 3-dependent pathway in HK-2 cells. Toxicology 231 (2007) 120-128
25. Lee N.J., Choi J.H., Koo B.S., Ryu S.Y., Han Y.H., Lee S.I., and Lee D.U. Antimutagenicity and cytotoxicity of the constituents from the aerial parts of Rumex acetosa. Biol. Pharm. Bull. 28 (2005) 2158-2161
26. Xia S.J., Shammas M.A., and Shmookler Reis R.J. Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol. Cell. Biol. 17 (1997) 7151-7158
27. Raderschall E., Stout K., Freier S., Suckow V., Schweiger S., and Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 62 (2002) 219-225
28. Baumann P., and West S.C. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem. Sci. 23 (1998) 247-251
29. Maacke H., Opitz S., Jost K., Hamdorf W., Henning W., Kruger S., Feller A.C., Lopens A., Diedrich K., Schwinger E., and Sturzbecher H.W. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int. J. Cancer 88 (2000) 907-913
30. Richardson C. RAD51, genomic stability, and tumorigenesis. Cancer Lett. 218 (2005) 127-139
31. Slupianek A., Hoser G., Majsterek I., Bronisz A., Malecki M., Blasiak J., Fishel R., and Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol. Cell Biol. 22 (2002) 4189-4201
32. Bello V.E., Aloyz R.S., Christodoulopoulos G., and Panasci L.C. Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem. Pharmacol. 63 (2002) 1585-1588
33. Qiao G.B., Wu Y.L., Yang X.N., Zhong W.Z., Xie D., Guan X.Y., Fischer D., Kolberg H.C., Kruger S., and Stuerzbecher H.W. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br. J. Cancer 93 (2005) 137-143
34. Takenaka T., Yoshino I., Kouso H., Ohba T., Yohena T., Osoegawa A., Shoji F., and Maehara Y. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int. J. Cancer 121 (2007) 895-900
35. Ohnishi T., Taki T., Hiraga S., Arita N., and Morita T. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem. Biophys. Res. Commun. 245 (1998) 319-324
36. Ko J.C., Ciou S.C., Cheng C.M., Wang L.H., Hong J.H., Jheng M.Y., Ling S.T., and Lin Y.W. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 29 (2008) 1448-1458
37. Peters G.J., van der Wilt C.L., van Moorsel C.J., Kroep J.R., Bergman A.M., and Ackland S.P. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther. 87 (2000) 227-253
38. Coldren C.D., Helfrich B.A., Witta S.E., Sugita M., Lapadat R., Zeng C., Baron A., Franklin W.A., Hirsch F.R., Geraci M.W., and Bunn Jr. P.A. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol. Cancer Res. 4 (2006) 521-528
39. Ko J.C., Hong J.H., Wang L.H., Cheng C.M., Ciou S.C., Lin S.T., Jheng M.Y., and Lin Y.W. Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Mol. Cancer Ther. 7 (2008) 3632-3641
40. Zhou X., Song B., Jin L., Hu D., Diao C., Xu G., Zou Z., and Yang S. Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb. Bioorg. Med. Chem. Lett. 16 (2006) 563-568
41. Lai G.H., Zhang Z., and Sirica A.E. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol. Cancer Ther. 2 (2003) 265-271
42. Ko J.C., Wang L.H., Jhan J.Y., Ciou S.C., Hong J.H., Lin S.T., and Lin Y.W. The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. Lung Cancer (2009)
43. Wang R., Wan Q., Zhang Y., Huang F., Yu K., Xu D., Wang Q., and Sun J. Emodin suppresses interleukin-1beta induced mesangial cells proliferation and extracellular matrix production via inhibiting P38 MAPK. Life Sci. 80 (2007) 2481-2488
44. Yi J., Yang J., He R., Gao F., Sang H., Tang X., and Ye R.D. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res. 64 (2004) 108-116
45. Fan R., Kumaravel T.S., Jalali F., Marrano P., Squire J.A., and Bristow R.G. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res. 64 (2004) 8526-8533
46. Arias-Lopez C., Lazaro-Trueba I., Kerr P., Lord C.J., Dexter T., Iravani M., Ashworth A., and Silva A. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep. 7 (2006) 219-224
47. Slupianek A., Schmutte C., Tombline G., Nieborowska-Skorska M., Hoser G., Nowicki M.O., Pierce A.J., Fishel R., and Skorski T. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol. Cell 8 (2001) 795-806
48. Battistutta R., Sarno S., De Moliner E., Papinutto E., Zanotti G., and Pinna L.A. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J. Biol. Chem. 275 (2000) 29618-29622
49. Kim K.Y., Shin H.K., Lee J.H., Kim C.D., Lee W.S., Rhim B.Y., Shin Y.W., and Hong K.W. Cilostazol enhances casein kinase 2 phosphorylation and suppresses tumor necrosis factor-alpha-induced increased phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and apoptotic cell death in SK-N-SH cells. J. Pharmacol. Exp. Ther. 308 (2004) 97-104
50. Parsels L.A., Morgan M.A., Tanska D.M., Parsels J.D., Palmer B.D., Booth R.J., Denny W.A., Canman C.E., Kraker A.J., Lawrence T.S., and Maybaum J. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol. Cancer Ther. 8 (2009) 45-54
51. Choudhury A., Zhao H., Jalali F., Al Rashid S., Ran J., Supiot S., Kiltie A.E., and Bristow R.G. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol. Cancer Ther. 8 (2009) 203-213
52. Chen G., Yuan S.S., Liu W., Xu Y., Trujillo K., Song B., Cong F., Goff S.P., Wu Y., Arlinghaus R., Baltimore D., Gasser P.J., Park M.S., Sung P., and Lee E.Y. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J. Biol. Chem. 274 (1999) 12748-12752
53. Kubler H.R., van Randenborgh H., Treiber U., Wutzler S., Battistel C., Lehmer A., Wagenpfeil S., Hartung R., and Paul R. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate 63 (2005) 385-394